作　　者： ; ; ;

机构地区： 中国农业大学食品科学与营养工程学院

出　　处： 《细胞生物学杂志》 2004年第4期357-361,共5页

摘　　要： 利用核受体与配体作用促进癌细胞分化和凋亡是治疗癌症的新方向。过氧化物酶体增殖物激活受体(PPARs)是一类参与多种生物学效应的核受体,目前已知有3种亚型:α、β和γ。PPARs除和脂质代谢、氧化还原状态、炎症、心血管疾病、糖尿病、肥胖等一系列生理过程密切相关外,PPARs的激活还对细胞的生长、分化甚至凋亡有重要的影响,尤其是PPARγ的激活在多种恶性肿瘤细胞中可促进细胞凋亡、抑制肿瘤生长。然而由于PPARs的表达具有极大的物种、组织特异性,使预临床实验的推广应用变得十分复杂。现仅就PPARs与细胞凋亡方面的最新研究进展及其在癌症预临床中的研究状况进行综述。 Induction of differentiation and apoptosis in cancer cells through ligands of nuclear hormone receptors is a novel and promising approach to cancer therapy. Peroxisome proliferator activated receptors (PPARs) are a family of related receptors implicated in a diverse array of biological processes, with 3 main isotypes known as PPARα, β and γ. PPARs play important roles in diverse physiological process, including lipid metabolism, inflammatory response, status of oxidoreduction, cardiovascular diseases, diabetes and obesity. Except these, PPARs modulate cellular proliferation , differentiation, and apoptosis. Emerging evidence indicate that PPARs and their ligands, especially PPARγ, are indeed important for the modulation of apoptosis in a wide variety of tumor cell lines. However, significant species and tissue differences in the expression of PPARs complicate the exploration of pre-clinical test data to humans. This paper is attempted to review the recent advances of investigation into the relationship between PPARs and apoptosis, as well as the response to PPAR ligands seen in pre-clinical models of human cancer.

关 键 词： 核受体 配体 癌细胞 分化 细胞凋亡 过氧化物酶体增殖物激活受体

领　　域： [生物学] [生物学]